Serum expression level of squamous cell carcinoma antigen, highly sensitive C-reactive protein, and CA-125 as potential biomarkers for recurrence of cervical cancer
- 1 January 2017
- journal article
- research article
- Published by Medknow in Journal of Cancer Research and Therapeutics
- Vol. 13 (4), 689-692
- https://doi.org/10.4103/jcrt.jcrt_414_17
Abstract
Objective: The aim of this study was to evaluate the serum expression levels of squamous cell carcinoma antigen (SCC-Ag), highly sensitive C-reactive protein (hs-CRP), and CA-125 as potential serum biomarkers for recurrence of cervical cancer. Methods: Eighty-six cervical cancer patients who received radical treatment were retrospectively included in this study from February 2011 to January 2014. Of the included 86 cases, 23 were recurred within the 36 months (recurrence group [RG]) and other 63 patients did not (non-RG [NRG]). The serum levels of SCC-Ag, hs-CRP, and CA-125 were examined and compared between the two groups. The prediction recurrence sensitivity, specificity area under the receiver operating characteristic curve were calculated by STATA11.0 software (http://www.stata.com). The correlation among SCC-Ag, hs-CRP, and CA-125 were analyzed by Pearson correlation test. Results: The serum levels of SCC-Ag, hs-CRP, and CA-125 were 1.29 (0.21–33.20) mg/mL, 4.78 (0.22–175.20) mg/mL, and 11.56 (2.028–123.66) IU/mL for NRG and 5.64 (0.50–136.80) mg/mL, 22.41 (0.56–588.90) mg/mL, and 25.41 (3.658–3687.00) IU/mL for RG, respectively. The serum levels of SCC-Ag, hs-CRP, and CA-125 in NG group were significant higher than those of NRG group (P < 0.05). The recurrence prediction sensitivity was 0.74, 0.65, and 0.74; specificity was 0.65, 0.63, and 0.58; area under the curve was 0.75, 0.66, and 0.67, respectively, for serum SCC-Ag, hs-CRP, and CA-125. Significant positive correlation between SCC-Ag and hs-CRP (rpearson = 0.20, P = 0.04), SCC-Ag and CA-125 (rpearson = 0.64, P < 0.001), hs-CRP and CA-125 (rpearson= –0.13, P = 0.56) was found in the RG patients. Conclusion: Serum SCC-Ag, hs-CRP, and CA-125 were higher in recurrence cervical patients which could be potential biomarkers for predicting cervical cancer recurrence risk.Keywords
This publication has 13 references indexed in Scilit:
- Squamous cell carcinoma antigen (SCC-Ag) during follow-up of cervical cancer patients: Role in the early diagnosis of recurrenceGynecologic Oncology, 2016
- Preventing Cervical Cancer in the United States: Barriers and Resolutions for HPV VaccinationFrontiers in Oncology, 2016
- Cancer statistics, 2014CA: A Cancer Journal for Clinicians, 2014
- Serum levels of IL-6, IL-8 and CRP as prognostic factors in epithelial ovarian cancerEuropean Cytokine Network, 2013
- Prognostic value of pre-treatment circulating monocyte count in patients with cervical cancer: Comparison with SCC-Ag levelGynecologic Oncology, 2012
- Use of serum squamous cell carcinoma antigen for follow-up monitoring of cervical cancer patients who were treated by concurrent chemoradiotherapyRadiation Oncology, 2010
- Prognostic Factors for Survival in Patients With Recurrent Cervical Cancer Previously Treated With RadiotherapyInternational Journal of Gynecologic Cancer, 2010
- C-reactive protein and ovarian cancer: a prospective study nested in three cohorts (Sweden, USA, Italy)Cancer Causes & Control, 2009
- Serum C-Reactive Protein as Independent Prognostic Variable in Patients with Ovarian CancerClinical Cancer Research, 2008
- Squamous Cell Carcinoma Antigen in Follow-Up of Cervical Cancer Treated With Radiotherapy: Evaluation of Cost-EffectivenessEndocrine, 2007